Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reassortant Avian Influenza Virus (H5+H7) Trivalent Vaccine, Inactivated (Strain Re-11, Re-12 and H7-Re-2)
- Development stage
- Unknown
- Lead developer
- Liaoning Yikang Biological
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a trivalent inactivated veterinary vaccine developed by Liaoning Yikang Biological for the prevention of avian influenza in poultry. It contains three reassortant strains: H5N1 (Strain Re-11 and Strain Re-12) and H7N9 (Strain H7-Re-2). The vaccine works by inducing active immunity through the production of neutralizing antibodies against the hemagglutinin proteins of the H5 and H7 subtypes, thereby protecting chickens, ducks, and geese from highly pathogenic avian influenza (HPAI). It is administered via injection and is part of the mandatory vaccination programs for poultry in certain regions to control the spread of zoonotic influenza viruses.
- Other names
- H5+H7 Trivalent vaccineReassortant Avian Influenza Virus (H5+H7) Trivalent vaccine, Inactivated (H5N1 Strain Re-11+Re-12, H7N9 Strain H7-Re-2)reassortant avian influenza virus (H5 + H7) trivalent vaccine, inactivated-Liaoning Yikang Biological-Avian influenza H5N1-Avian influenza H7N9-inactivated vaccine-Avian influenza in poultry (H5N1, H7N9)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Reassortant Avian Influenza Virus (H5+H7) Trivalent Vaccine, Inactivated (Strain Re-11, Re-12 and H7-Re-2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reassortant Avian Influenza Virus (H5+H7) Trivalent Vaccine, Inactivated (Strain Re-11, Re-12 and H7-Re-2).